Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2016-09-20 Interim / Quarterly Rep…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Half-yearly financial statements 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Mid-Year Report 2016' and contains 'Consolidated Interim Financial Statements' and a 'Management Report' for the period from January 1, 2016, to June 30, 2016. It includes detailed financial analysis, business performance reviews, and operational updates for the first half of the year. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2016
2016-09-20 German
Formycon AG: Formycon Expands Board and Appoints Pharma Top Manager Dr. Stefan Glombitza as Chief Operating Officer
Board/Management Information Classification · 100% confidence The document is a press release dated July 7, 2016, announcing a change in senior management: the appointment of Dr. Stefan Glombitza as Chief Operating Officer (COO) and the expansion of the Board. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific personnel change.
2016-07-07 English
Formycon AG: Formycon CEO Dr. Carsten Brockmeyer once again honored as one of the world's most influential people in the medicines industry
Board/Management Information Classification · 99% confidence The document is a press release dated June 14, 2016, announcing that the CEO of Formycon AG, Dr. Carsten Brockmeyer, was honored as one of the world's most influential people in the medicines industry. It is categorized under 'Change of Personnel/Miscellaneous' and is disseminated via DGAP, which handles various corporate news. This type of announcement, focusing on executive recognition and general company news that doesn't fit specific financial reporting categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Corporate News announcement. Since 'Regulatory Filings (RNS)' is defined as the fallback for miscellaneous filings that do not neatly fit elsewhere, and this is a standard press release about an executive honor, RNS is the most appropriate code.
2016-06-14 English
Jahresabschluss 2015
Annual Report Classification · 100% confidence The document is titled 'Geschäftsbericht 2015' (Annual Report 2015) for Formycon AG. It contains comprehensive sections typical of an annual report, including the management report (Wirtschaftsbericht), consolidated financial statements (Konzernbilanz, Gewinn- und Verlustrechnung), notes to the financial statements (Anhang), the auditor's report (Bestätigungsvermerk des Abschlussprüfers), and the report of the supervisory board (Bericht des Aufsichtsrats). Given the length and the inclusion of full financial statements and management commentary for the fiscal year, it is classified as an Annual Report (10-K). FY 2015
2016-06-12 German
Formycon AG: Formycon Publishes Figures for the First Quarter of 2016
Earnings Release Classification · 100% confidence The document is titled "Formycon Publishes Figures for the First Quarter of 2016" and explicitly details financial results for the period (sales revenues, EBITDA, quarterly result) and operational milestones (patient enrollment in Phase III study). This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, typically highlighting key figures. It is not a comprehensive Interim Report (IR) or Annual Report (10-K), nor is it merely an announcement of a report's publication (RPA), as it contains the actual figures. The presence of 'Quarter Results' in the keywords further supports this classification. Q1 2016
2016-05-19 English
Formycon AG: Formycon ends 2015 fiscal year with successful results
Earnings Release Classification · 100% confidence The document is titled 'Formycon ends 2015 fiscal year with successful results' and contains key financial metrics for the year 2015, including turnover (Euro 16.9 million), EBITDA, and net profit. It explicitly mentions 'Final Results/Forecast' in the header and discusses operational success and financial position at the end of the fiscal year. This content strongly indicates a summary of annual financial performance, which aligns best with the Annual Report (10-K) category, although this specific document appears to be an Earnings Release (ER) or a preliminary summary preceding the full 10-K filing, given its format as a 'Press Release' disseminated via DGAP. Since it provides detailed financial figures for the full fiscal year (2015) and is not just a brief announcement of results, it is closer to an ER or MDA than a simple RPA. However, the content is a summary of the *full year's* results, making it a strong candidate for an Earnings Release (ER) which often summarizes the annual performance before the comprehensive 10-K is filed, or potentially a Management Discussion and Analysis (MDA) if it were more narrative. Given the structure (Press Release format summarizing annual performance highlights and key figures), Earnings Release (ER) is the most appropriate fit among the provided options for a comprehensive year-end summary announcement. FY 2015
2016-04-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.